leisure time -WSS

leisure time

author：focus 2025-10-02 09:47:18 - browse：1552

The biotech company Acelyrin, which raised more than $500 million in an IPO this year, ran into its first major setback Monday as its investigational anti-inflammatory drug missed the primary goal in a pivotal clinical trial.

Acelyrin’s medicine, a subcutaneous treatment called izokibep, is meant to clear up lesions for patients with the common skin disease hidradenitis suppurativa, or HS, an inflammatory disorder that leads to abscesses and scars. But after 16 weeks of treatment, patients who received izokibep did not show significant improvements compared to those taking a placebo, failing the study’s primary endpoint.

Acelyrin’s share price fell more than 60% in after-hours trading Monday.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Patients, doctors press FTC to beef up hospital merger scrutiny

WSS

Illinois Supreme Court finds assault weapons ban constitutional

House panel takes first step toward fixing drug shortages

Indictment alleges Trump's ex

YouTube cracks down on misinformation on cancer treatment

How the messy conversation about Dolly changed bioethics

Maui wildfire now ranks as the fifth

knowledge

leisure time

knowledge

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Bird flu researchers hone in on Finland’s mink farms

Trump demands the U.S. pay no more for drugs than other countries … again

Biogen’s boardroom scandal saddles CEO with first crisis

Dobbs anniversary: the lost opportunity of abortion as health care

Timeline: How the deadly wildfires took over Maui day by day

Dobbs anniversary: the lost opportunity of abortion as health care

FDA panel to weigh safety of artificial wombs for preterm births

Affirmative action in medical school literally saved lives

Maui wildfire now ranks as the fifth

leisure time

YouTube cracks down on misinformation on cancer treatment

Health AI: on the border between health care and tech

Biden administration begins canceling student loan debt for 804,000 borrowers

Illumina slashes 2023 revenue projections yet again

Patients, digital health players weigh in on FTC's data privacy plan

Why the drug industry's warnings on the IRA's impact fall short

hotspot

entertainment

leisure time

leisure time